Azacytidine and Valproic Acid in Patients With Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Advanced Cancers
Interventions
DRUG

Azacitidine

Starting Dose 20 mg/m\^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.

DRUG

Valproic Acid

Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00496444 - Azacytidine and Valproic Acid in Patients With Advanced Cancers | Biotech Hunter | Biotech Hunter